SOPHiA GENETICS CPO gets new option and RSU grant
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings.
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings. She was granted an option for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. Following these awards and a correction to a prior report, her directly held ordinary shares are reported as 224,248.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 176,659 shares
Grant/Award
2 txns
Insider
Valente Manuela
Role
Chief People Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 104,790 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 71,869 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 104,790 contracts (Direct);
Ordinary Shares — 224,248 shares (Direct)
Footnotes (3)
- F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- F2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 71,869 ordinary shares due to an inadvertent error. The correct amount is 224,248 ordinary shares.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Stock option grant size: 104,790 shares
Option exercise price: $5.04 per share
Option expiration: April 2, 2036
+4 more
7 metrics
Stock option grant size
104,790 shares
Share option granted on April 2, 2026
Option exercise price
$5.04 per share
Exercise price for 104,790-share option
Option expiration
April 2, 2036
Expiration date of share option
RSU grant size
71,869 RSUs
RSU grant under 2021 Equity Incentive Plan
Shares beneficially owned
224,248 ordinary shares
Corrected amount following reported transactions
Initial RSU vesting
25% on April 2, 2027
First vesting tranche for RSU grant
Remaining RSU vesting period
Through April 2, 2030
Remaining RSUs vest quarterly to 2030
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vest, beneficially owned, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"grant made under the Issuer's 2021 Equity Incentive Plan."
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
beneficially owned financial
"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did SOPH Chief People Officer Manuela Valente receive?
Manuela Valente received a share option for 104,790 ordinary shares at a $5.04 exercise price and 71,869 restricted stock units. These compensation awards increase her potential ownership in SOPHiA GENETICS SA if vesting and, for options, future exercises occur.
How do the new RSUs for SOPH’s Manuela Valente vest over time?
The 71,869 RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. Vesting is conditioned on her continued service with SOPHiA GENETICS SA during this period.
What are the terms of Manuela Valente’s new SOPH stock option grant?
The grant covers 104,790 ordinary shares at a $5.04 exercise price and expires April 2, 2036. Twenty-five percent vests on April 2, 2027, and the rest vests in equal monthly installments through April 2, 2030, subject to continued service.
Why was this Form 4/A amendment filed for SOPH’s Manuela Valente?
The amendment corrects the amount of securities beneficially owned after the reported transaction. A prior Form 4 had inadvertently reported 71,869 ordinary shares; this filing states the correct total is 224,248 ordinary shares following the transaction.
Are Manuela Valente’s new SOPH awards open-market purchases or compensation grants?
Both transactions are coded as grants or awards, not open-market purchases. The option and RSU awards were made under SOPHiA GENETICS SA’s 2021 Equity Incentive Plan as part of her compensation, with no cash purchase price reported per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
